A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer
Status:
Recruiting
Trial end date:
2026-01-31
Target enrollment:
Participant gender:
Summary
A national, prospective, multi-center, open-label, single arm phase II trial investigating
the efficacy and safety of bevacizumab plus erlotinib in patients with advanced cancers which
harbors genomic alterations in Krebs cycle
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Boryung Pharmaceutical Co., Ltd Korean Cancer Study Group